Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please e-mail your request to and we will make every effort to respond as soon as possible. Please read our terms for usage.

As of March 5, we've updated our corporate brand. We are in the process of updating our media library - in the meantime, please find new materials below.

Key Facts updated Jan 2019

Chief Executive Officer:
New York City
Web Address:
NYSE Listing:
Net Sales:
$22.6 billion in 2018
R&D Investment:
$5.1 billion* which included the discovery and development of new medicines for patients
*This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items. 
2018 Largest-Selling Brands:

OPDIVO®, $6.7 billion

ELIQUIS®, $6.4 billion

ORENCIA®, $2.7 billion

SPRYCEL®, $2.0 billion

YERVOY®, $1.3 billion

BARACLUDE®, $744 million

SUSTIVA® franchise, $283 million

REYATAZ® franchise, $427 million

Hepatitis C franchise, $17 million

Selected Key Products:

Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol Myers Squibb Corporate B-roll

Overview B-roll

This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.

Usage Rights & Restrictions: These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.

Scientific Media Resources

Disease State Infographics

Disease State Infographics